Medical device maker sees profit, shares dip.
|
The med-tech giant’s shares tick upward as defibrillator market stabilizes.
|
Boston Scientific’s CFO stands ground that buying troubled heart device maker Boston Scientific was the best thing the company ever did.
|
Investors look to get insight on the medical device industry’s coming year with top chief Art Collins.
|
The federal agency publishes plan that could improve post-market device safety.
|
Medical device maker squirrels away the money to deal with the legal woes of Guidant.
|
Boston Scientific shares dip 7 percent after warnings some devices could cause problems.
|
Device maker partners with Big Blue to develop system that lets doctors test and reprogram defibrillators and pacemakers.
|
Medical device maker Guidant gets slapped with a lawsuit over its secrecy policy.
|
Recent recalls stir discussion on the reporting and replacement of faulty cardiac devices.
|
Boston Scientific gets U.S. government clearance to acquire troubled heart device maker Guidant.
|
Harvard Medical School says implantable heart devices are incompatible with the screening tool.
|
An independent panel suggests how the troubled heart device maker can better its patient safety communication skills.
|
The problem-plagued company warns doctors about possible battery troubles in some of its defibrillators.
|
Europe probes Boston-Guidant deal; Inamed’s outperforming wrinkle filler; polls shows Americans like techy medicine.
|
Inspectors say heart device maker failed to report in a timely manner on repair work for certain defibrillator products.
|
Boston Scientific and Guidant left Johnson & Johnson all alone by the telephone. So just who will J&J call?
|
Heart device maker terminates agreement with Johnson & Johnson after the deadline expires for raised bid.
|
The heart device maker's story takes a new twist as secret documents cause a stir.
|
Heart device maker concludes Boston Scientific $27B offer beats J&J at $24.2B but stops short of recommending it.
|
Page
1
of
2
|